CYTR

[njshiva]

this one is looking good. 

[Holygrale]

This one is gaining momentum especially with todays follow thru volume............

Nice article today..........  http://articles.moneycentral.msn.com/Investing/StrategyLab/Rnd14/P2/cnbcchampjournal060831.aspx


"Lou Gehrig and a tiny drug stock
advertisement


Buy $10,000 worth of CytRx (CYTR, news, msgs) at the open.
I am buying $10,000 worth of CytRx (CYTR, news, msgs), a biopharmaceutical research and development company that just received a huge $24 million royalty payment from the nonprofit ALS Charitable Remainder Trust for a mere 1% stake of the company's future arimoclomol drug sales.

The deal is relatively nondilutive and looks to help the company speed up its research on ALS (also know as Lou Gehrig's disease), with its lead molecule drug candidate arimoclomol currently in late stage 2 development. The early results indicate that arimoclomol may show promise as a treatment for Huntington's, Alzheimer's and Parkinson's diseases, as well as stroke and cystic fibrosis.

At $24 million for just a 1% stake in sales, we could mathematically imply that the CytRx, as a whole, could be worth in excess of $2.4 billion, or more than $30 per share. With the stock trading at levels giving it about a $100 million market cap, I think there's a lot of upside here, given the funding and increased visibility of the potential value of arimoclomol and company's other drug pipelines focusing on treatment of HIV, obesity, type 2 diabetes and cytomegalovirus using RNAi technology. The company is targeting multibillion-dollar markets.

While it may take awhile to realize the true value for CYTR, I believe the company is on the right path to eventual success. The stock looks extremely cheap here, while the potential could be huge.

Full disclosure: I own shares of CytRx"

[Holygrale]

Gaining some momentum...............

[kslifka]

CYTR's been disappointing .

At least the Gap is almost filled.  Volume still good and 50dma is turning up.

[setravis]

Post a chart , don't have anymore time for comments tonight.
But it is bouncing off the 200-day MA.

[D&Data]

an entry between 1.3...1.4 ?

Id..

[setravis]

AP
Volume Spikes: VWPT CYTR LPTH SFUN
Friday October 13, 2:37 pm ET 
Viewpoint Shares Trade Unusually Heavily After Company Warns of Softer Sales


NEW YORK (AP) -- The following companies showed unusually heavy volume in Friday trading on the Nasdaq around 2 p.m. Higher-than-normal volume can indicate increased activity by institutions such as mutual funds and insurance companies. Upward stock movement on such volume can show increased confidence among investors, while selling can signal further downward pressure on a stock.
ADVERTISEMENT


Shares of Viewpoint Corp. traded in unusually heavy volume after the New York-based Web search and advertising company lowered its full-year revenue outlook because of soft spending on advertising.

Viewpoint said it expects sales in a range of $17 million to $20 million in 2006, lower than its original outlook of $26 million to $30 million.

More than 3.5 million Viewpoint shares had changed hands by 2 p.m., more than 10 times the normal daily volume of the stock.

Biopharmaceutical research company CytRx Corp. traded heavily despite a lack of any notable news. The company didn't issue any press releases and no analysts released research on the company.

But trading volume exceeded 10.5 million at 2 p.m., far higher than typical trading volume of 864,067 shares.

Shares of LightPath Technologies Inc. traded extraordinarily heavily Friday after the Orlando, Fla.-based maker of fiber-optic products projected sales growth of 63 percent in the fiscal first quarter.

The company expects sales of $4.4 million in the quarter, compared with sales of $2.7 million in the same quarter last year. The defense market segment and communications segment both contributed strong growth, the company said.

Trading volume in LightPath shares reached 2.3 million by 2 p.m., while average daily trading is only 23,288 shares. The shares were up 48.1 percent.

Saifun Semiconductors Ltd., which licenses semiconductor technology, said early Friday it lost a licensing deal from a significant customer, and the news propelled the company's shares into heightened trading.

Saifun, based in Israel, said customer German semiconductor maker Infineon Technologies AG is scaling back its manufacturing of nitride read-only memory chips, which Saifun has patent rights to and collects licensing fees on.

Infineon is not expected to pay licensing or servicing fees to Saifun, Saifun said.

Nearly 2.2 million shares of Saifun had changed hands by 2 p.m., well more than the daily average of 77,518 shares. The stock fell nearly 27 percent.

[stocks2watch2]

 

CytRx says drug granted orphan drug status in Europe
Reuters - October 31, 2006 8:45 AM ET
   

Related Quotes
Symbol   Last Chg
CYTR Trade 1.31 0.00
Real time quote.
 
CHICAGO, Oct 31 (Reuters) - CytRx Corp.(CYTR) said on Tuesday its lead drug candidate won European orphan drug status for the treatment of ALS, a disease that attacks brain and spinal column nerve cells that control muscle movement.

CytRx said the orphan drug designation would give the company 10 years of market exclusivity in the European Union in the event that its drug, arimoclomol, is approved. The status also provides incentives such as reduced fees for protocol assistance and scientific advice.

ALS, or amyotrophic lateral sclerosis, causes increasing muscle weakness, inability to control movement and problems with speaking, swallowing and breathing. About half of ALS patients die within 18 months of diagnosis and 80 percent die within five years.

[for3J1M]

great posts stocks2watch2! applaud! keep up the good work!  i saw you post on the siga board about cytr. i bought some at 1.44 and 1.45.i almost sold when no news came out at the conf. glad i didnt!!!   i wasnt here for the open this morning. hoping for a second surge today.

[for3J1M]

shes moving again

[for3J1M]

 nice close today at 1.80 

[stocks2watch2]

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported financial results for the three months and nine months ended September 30, 2006.

"The past several months have been highly productive at CytRx. Importantly, as announced in September, we met the primary endpoints of safety and tolerability in our Phase IIa clinical trial with our lead molecular chaperone compound arimoclomol for the treatment of ALS, also known as Lou Gerhig's disease," said Steven A Kriegsman, President and CEO of CytRx. "We also enhanced our cash position through a non-dilutive $24.5 million royalty agreement with the privately-funded ALS Charitable Remainder Trust. It is gratifying to enter into this novel transaction in which we received resources to support our continued development of arimoclomol in return for a royalty of one-percent of our potential worldwide arimoclomol sales. Notably, the beneficiary of the ALS Charitable Remainder Trust is The Greater Los Angeles chapter of The ALS Association, which shares our commitment for treating patients with this life-threatening disease.

"We are making headway toward our plan to initiate a Phase IIb clinical trial with arimoclomol in ALS in the third quarter of 2007, subject to U.S. Food and Drug Administration (FDA) approval. Given the life-threatening nature of this disease and the lack of viable treatment options, we believe that positive safety and efficacy results from the Phase IIb trial could be sufficient for arimoclomol product registration in this indication," he added.

"We also continue to make progress with our RNAi technology platform with programs aimed toward addressing major diseases, including type 2 diabetes and obesity," said Mr. Kriegsman. "RNAi is a technology that has received significant recent scientific and media interest, and we believe CytRx is at the forefront of this technology. We are advised by world class scientists in the field of RNAi drug development, including Craig C. Mello, Ph.D., who this year was named co-winner of the Nobel Prize in medicine for the discovery of RNAi."

[stocks2watch2]

Review of Financial Results

For the third quarter of 2006, CytRx reported a net loss of $3.0 million, or $0.04 per share, compared with a net loss of $3.5 million, or $0.06 per share, for the third quarter of 2005. Revenue for the three months ended September 30, 2006 was $776,000 and consisted primarily of service revenue from the research and development aspects of the royalty transaction with the ALS Charitable Remainder Trust. CytRx will continue to recognize the balance of the deferred revenue recorded from the royalty transaction with the ALS Charitable Remainder Trust on a proportional performance basis. Revenue for the three months ended September 30, 2005 was $10,000 and consisted entirely of license fees paid for CytRx's TranzFect vaccine adjuvant technology. Potential revenues from all future license fees under pre-existing agreements are dependent upon successful development milestones being achieved by the licensee.

Research and development expenses were $1.1 million for the third quarter of 2006, compared with $2.0 million for the third quarter of 2005. This decrease was due primarily to the completion of the Phase IIa clinical trial for arimoclomol in the third quarter of 2006 in contrast to the higher expenses associated with the initiation of the Phase IIa clinical trial in 2005. General and administrative expenses were $2.3 million for the third quarter of 2006, compared with $1.5 million a year earlier. The higher level of general and administrative expenses incurred in the third quarter of 2006 resulted primarily from increased salary and benefit expenses of $530,000 and professional fees of $330,000. On January 1, 2006, CytRx adopted Statement of Financial Accounting Standards No. 123(R) (SFAS 123(R)), "Share-Based Payment." As a result, CytRx recorded approximately $379,000 in stock-based compensation expense for the third quarter of 2006. Results for the third quarter of 2005 do not include SFAS 123(R) compensation expenses.

CytRx reported a net loss for the nine months ended September 30, 2006 of $12.6 million, or $0.19 per share, compared with a net loss of $11.5 million, or $0.20 per share, for the nine months ended September 30, 2005. Revenue for the first nine months of 2006 was $837,000 and consisted primarily of revenue recorded from the royalty transaction with CytRx's ALS Charitable Remainder Trust, while revenue of $11,500 for the first nine months of 2005 consisted entirely of license fees paid with respect to CytRx's TranzFect vaccine adjuvant technology. The Company recorded approximately $1.1 million in stock-based compensation expense for the first nine months of 2006.

As of September 30, 2006, cash, cash equivalents and short-term investments totaled $33.7 million, compared with $8.3 million as of December 31, 2005. The increase reflects net proceeds of approximately $12.4 million from the private sale of common stock and warrants to a group of institutional investors in March 2006 and $24.5 million from the privately-funded ALS Charitable Remainder Trust for a one-percent royalty interest in worldwide sales of arimoclomol for ALS. Working capital was $31.5 million as of September 30, 2006, as compared with $6.3 as of December 31, 2005.

Third quarter 2006 and recent highlights:

In September:

-- CytRx announced that arimoclomol met the primary endpoints of safety and tolerability in its Phase IIa trial in patients with ALS. In addition, CytRx announced that the Phase IIa trial results demonstrated that arimoclomol crossed the "blood:brain barrier," and indicated a non-statistically-significant trend of improvement in functional capacity as measured by the Revised ALS Functional Ration Scale in the arimoclomol high dose group as compared with untreated patients. Based on these results, CytRx plans to initiate a Phase IIb trial with arimoclomol in ALS in the third quarter of 2007, subject to FDA approval. An open label extension of the Phase IIa clinical trial remains ongoing, and CytRx expects that it will be completed in February 2007.

-- CytRx received $24.5 million in a non-dilutive agreement with the privately-funded ALS Charitable Remainder Trust to fund continued development of arimoclomol and alternatives for the treatment of ALS in return for a royalty of one percent of CytRx's potential worldwide sales of arimoclomol for ALS. The Greater Los Angeles Chapter of The ALS Association is the beneficiary of the Trust.

-- CytRx was awarded a Small Business Innovative Research (SBIR) grant of approximately $222,000 by the National Institute of Diabetes and Digestive and Kidney Diseases, a part of the National Institutes of Heath (NIH), based on CytRx's small molecule and structure-based drug design expertise.

In October:

-- CytRx presented new preclinical data demonstrating that orally-administered arimoclomol improved the functional recovery of rat motor skills damaged by stroke. This early-stage data supports the potential of arimoclomol as a therapeutic treatment in multiple clinical indications.

-- Arimoclomol was granted orphan medicinal product status for the treatment of ALS by the European Commission, providing for market exclusivity in the European Union for 10 years in the event that arimoclomol receives marketing approval, and provides for incentives such as reduced fees for protocol assistance and scientific advice.

-- Mr. Kriegsman received the Lou Gehrig Memorial Award from the Muscular Dystrophy Association, which was presented in recognition of CytRx's dedication to finding a cure for ALS.

CytRx has presented company overviews at the following recently held investment conferences:

-- In August, Scott Wieland, Ph.D., CytRx Vice President of Clinical and Regulatory Affairs, presented at the California Stock Report's 2006 Southern California Investor Conference.

-- In September, Mr. Kriegsman and Jack Barber, Ph.D., CytRx's Senior Vice President of Drug Development, presented at the UBS Global Life Sciences Conference.

-- In October, Dr. Barber presented at the 2006 BIO InvestorForum.

-- Last week, Mr. Kriegsman and Dr. Barber presented at the 8th Annual Rodman & Renshaw Healthcare Conference.

About Arimoclomol

Arimoclomol is one of CytRx's three orally-administered, small molecule compounds. This small molecule drug candidate is believed to function by stimulating a normal cellular protein repair pathway through the activation of "molecular chaperones." Since damaged proteins called aggregates are thought to play a role in many diseases, CytRx believes that activation of molecular chaperones could have therapeutic efficacy for a broad range of diseases. The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS. Arimoclomol has also been granted orphan medicinal product status for the treatment of ALS by the European Commission.

About ALS

ALS is a progressive degeneration of the brain and spinal column nerve cells that control the muscles that allow movement. Over a period of months or years, ALS causes increasing muscle weakness, inability to control movement and problems with speaking, swallowing and breathing. According to the ALS Survival Guide, 50% of ALS patients die within 18 months of diagnosis and 80% die within five years. More than 120,000 people are living with ALS worldwide.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, the Company announced that its lead clinical-stage compound arimoclomol met the primary endpoints of safety and tolerability in its Phase IIa trial in patients with ALS. CytRx has a broad-based strategic alliance with the University of Massachusetts Medical School to develop novel compounds in the areas of ALS, obesity, type 2 diabetes and cytomegalovirus using RNAi technology. The Company has a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. CytRx Drug Discovery division, located in Worcester, Massachusetts, focuses on the use of RNAi technologies to develop small molecule and RNAi therapeutics to treat obesity and type 2 diabetes. For more information, visit CytRx's Web site at www.cytrx.com.
                       
       
       

                                 
                             
                             

[for3J1M]

i admit it, i got scared!   sold 3/4. locked in profits at 1.86

[stocks2watch2]

i admit it, i got scared!   sold 3/4. locked in profits at 1.86

Good job, take them profits when you have them. I'm selling a few @ 1.93. I will hold the rest as I think we go over 2.00 and maybe a new 52 week high before years end.